Short Interest Runner: Can Biospecifics Tech Corporation (NASDAQ:BSTC)’s Tomorrow be Different? The Stock Had Increase in Shorts

November 28, 2016 - By Vivian Park   ·   0 Comments

Short Interest Runner: Can Biospecifics Tech Corporation (NASDAQ:BSTC)’s Tomorrow be Different? The Stock Had Increase in Shorts

The stock of Biospecifics Tech Corporation (NASDAQ:BSTC) registered an increase of 9.61% in short interest. BSTC’s total short interest was 166,500 shares in November as published by FINRA. Its up 9.61% from 151,900 shares, reported previously. With 23,000 shares average volume, it will take short sellers 7 days to cover their BSTC’s short positions. The short interest to Biospecifics Tech Corporation’s float is 4.09%. About 896 shares traded hands. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has risen 39.17% since April 25, 2016 and is uptrending. It has outperformed by 33.16% the S&P500.

BioSpecifics Technologies Corp. is a biopharmaceutical company. The company has a market cap of $357.00 million. The Firm is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. It has a 32.7 P/E ratio. The Firm has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development.

Insitutional Activity: The institutional sentiment decreased to 1.42 in 2016 Q2. Its down 1.01, from 2.43 in 2016Q1. The ratio turned negative, as 7 funds sold all BioSpecifics Technologies Corp. shares owned while 14 reduced positions. 8 funds bought stakes while 43 increased positions. They now own 3.62 million shares or 3.75% more from 3.49 million shares in 2016Q1.
First Manhattan Com holds 43,380 shares or 0.01% of its portfolio. Acadian Asset Lc has 216,495 shares for 0.04% of their US portfolio. Tocqueville Asset Mgmt L P has 20,000 shares for 0.01% of their US portfolio. Manufacturers Life Insurance Communications The owns 4,098 shares or 0% of their US portfolio. Blackrock Fund Advsr accumulated 139,760 shares or 0% of the stock. Rk Capital Management Ltd has 234,159 shares for 1.67% of their US portfolio. Adams Diversified Equity Fund accumulated 0.02% or 6,800 shares. The Switzerland-based Credit Suisse Ag has invested 0% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Clarivest Asset Management Limited Liability owns 8,307 shares or 0.01% of their US portfolio. State Street Corporation last reported 0% of its portfolio in the stock. Northern Tru Corp last reported 78,169 shares in the company. Dupont Capital Corporation last reported 8,749 shares in the company. Mufg Americas Holdg has invested 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Blackrock Advsr Limited Liability Corporation owns 25,738 shares or 0% of their US portfolio. Morgan Stanley, a New York-based fund reported 203 shares.

Insider Transactions: Since August 23, 2016, the stock had 0 buys, and 7 sales for $1.53 million net activity. On Thursday, September 15 Wegman Thomas sold $127,751 worth of the stock or 3,100 shares. $135,350 worth of BioSpecifics Technologies Corp. (NASDAQ:BSTC) was sold by Wegman Toby on Tuesday, September 13.

BSTC Company Profile

BioSpecifics Technologies Corp. (BioSpecifics), incorporated on November 1, 1990, is a biopharmaceutical company. The Firm is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Firm has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. The Company’s injectable collagenases are marketed for indications, such as Dupuytren’s contracture and Peyronie’s disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren’s contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.

More notable recent BioSpecifics Technologies Corp. (NASDAQ:BSTC) news were published by: Prnewswire.com which released: “BioSpecifics Technologies Corp. Reports Third Quarter 2016 Financial Results” on November 09, 2016, also Prnewswire.com with their article: “BioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of …” published on November 17, 2016, Quotes.Wsj.com published: “News BioSpecifics Technologies Corp.BSTC” on February 12, 2011. More interesting news about BioSpecifics Technologies Corp. (NASDAQ:BSTC) were released by: Prnewswire.com and their article: “BioSpecifics Technologies Corp. to Report Third Quarter 2016 Financial Results …” published on November 02, 2016 as well as Seekingalpha.com‘s news article titled: “BioSpecifics Technologies Corp. Has A 6-Year Expiration Date” with publication date: August 03, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Vivian Park


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>